Literature DB >> 24343602

Platelet indices in retinal vein occlusion in hypertensive patients.

Ercan Varol1, Mehmet Ozaydin.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 24343602      PMCID: PMC3959103          DOI: 10.4103/0301-4738.121136

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Sir, We read the article by Onder et al. with great interest.[1] The authors measured the mean platelet volume (MPV) in hypertensive patients with branch retinal vein occlusions (BRVO). They found that hypertensive patients with BRVO have significantly higher MPV than controls, suggesting higher platelet activity. This is an interesting study. However, we want to make some minor criticisms about this study. In generally method of MPV assessing is correct. They studied the blood samples within 2 h to prevent ethylenediaminetetraacetic acid induced swelling. On the other hand, there are significant associations of MPV with diabetes mellitus, pre-diabetes, hypertension, hypercholesterolemia, obesity, metabolic syndrome, smoking, statin and some antihypertensive drug use and atrial fibrillation.[23] These factors can influence the MPV values. Although the authors excluded some chronic diseases, data of cardiovascular diseases including coronary artery disease, body mass index, antihypertensive drugs and statin use is lacking. The mean age of the patients is 62-year-old and some of them may have cardiovascular disease at this age. It has also been shown that some antihypertensive drug and statin use can affect MPV values.[456] When we look at, nearly all patients and controls are hypertensive. However, there is no data about drugs used in these patients and controls. We believe that, it would be useful, if the authors provided data about these risk factors and their possible relationship with MPV and hypercholesterolemia. In our previous study, we found that MPV was significantly elevated in patients with deep vein thrombosis compared with controls.[7] Platelet activation might occur with a similar mechanism in patients with BRVO and deep vein thrombosis. We think that patients with BRVO are under risk of other cardiovascular disorders and must be investigated from this aspect.
  7 in total

1.  Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients.

Authors:  Darija Bakovic; Nediljko Pivac; Davor Eterovic; Ivan Palada; Zoran Valic; Branka Paukovic-Sekulic; Zeljko Dujic
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-04       Impact factor: 2.557

2.  Mean platelet volume in patients with prehypertension and hypertension.

Authors:  Ercan Varol; Selahattin Akcay; Atilla Icli; Habil Yucel; Emel Ozkan; Dogan Erdogan; Mehmet Ozaydin
Journal:  Clin Hemorheol Microcirc       Date:  2010       Impact factor: 2.375

3.  Mean platelet volume is increased in patients with deep vein thrombosis.

Authors:  Mehmet Gulcan; Ercan Varol; Mustafa Etli; Fatih Aksoy; Mustafa Kayan
Journal:  Clin Appl Thromb Hemost       Date:  2011-11-22       Impact factor: 2.389

4.  Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy.

Authors:  Sunil Nadar; Andrew D Blann; Gregory Y H Lip
Journal:  Ann Med       Date:  2004       Impact factor: 4.709

Review 5.  The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases.

Authors:  L Vizioli; S Muscari; A Muscari
Journal:  Int J Clin Pract       Date:  2009-10       Impact factor: 2.503

6.  The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.

Authors:  Erkan Coban; Berna Afacan
Journal:  Platelets       Date:  2008-03       Impact factor: 3.862

7.  Relation between platelet indices and branch retinal vein occlusion in hypertensive patients.

Authors:  Halil Ibrahim Onder; Ali Cagri Kilic; Murat Kaya; Serkan Bulur; Elif Onder; Murat Tunc
Journal:  Indian J Ophthalmol       Date:  2013-04       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.